The global cancer biomarkers market size is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers. As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630
List of Key Cancer Biomarker Market Manufacturers:
- Myriad RBM
- Abbott
- Hoffmann-La Roche Ltd.
- BioVision Inc.
- Thermo Fisher Scientific
- R&D System
- Bio-Rad Laboratories, Inc.
- Sino Biological Inc.
- CENTOGENE N.V.
- Sino Biological Inc.
- Axon Medchem
Report Highlights
The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website.
Market Drivers
Rise in Prevalence of Cancer Worldwide to Augment Growth
The increasing prevalence of cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue in the coming years.
The global cancer biomarkers market size is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide.
Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers.
As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630List of Key Cancer Biomarker Market Manufacturers:Myriad RBMAbbottHoffmann-La Roche Ltd.BioVision Inc.Thermo Fisher ScientificR SystemBio-Rad Laboratories, Inc.Sino Biological Inc.CENTOGENE N.V.Sino Biological Inc.Axon MedchemRequest a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cancer-biomarkers-market-100630Report HighlightsThe report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities.
It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights.
The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography.
The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market.
Market Overview:The Global Healthcare Contract Research Outsourcing Market held USD 36.9 billion in 2020 and is to grow with a CAGR of 6.4% from 2020-2030.
With rising privatization of clinical trials, the outsourcing to developed countries is on the increase.
Companies in pharmaceutical sector have begun outsourcing R activities which are complex and require regular monitoring.
Healthcare CROs functions and manages the processes of bringing new products to the market according to the customer's timeline provided.
Emerging economies like Japan, India and China are chosen to outsource business.
Key players are in the process of purchasing other contract research organizations, in addition to partnerships, to achieve leverage.Market Dynamics and Factors:Increasing investment in R programs, growing demand for outsourcing activities due to time and cost constraints in the healthcare sector are key factors expected to drive the healthcare contract research outsourcing market growth in the years to come.
Factors such as the increasing R activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.The Research Antibodies Market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793Market Segmentation:-On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016.
This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.Based on technology, the western blotting segment accounted for the largest share of the Research Reagents Market.
Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.Based on application, the proteomics segment accounted for the largest share of the Research Reagents Market.
The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R expenditure, and availability of funds from various organizations.Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the Research Antibodies and Reagents Market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.Key Market Opportunities: - 1 High Growth Opportunities in Emerging Markets 2 Increasing Demand for Personalized Medicine and Protein Therapeutics 3 Growths in Stem Cell and Neurobiology Research 4 Increasing Focus on Biomarker DiscoveryRegional Analysis:-North America accounted for the largest share of the Research Antibodies and Reagents Market in 2016, followed by Europe.
This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793Top Key Players:-The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).
Market HighlightsGlobal Chemiluminescence Immunoassay (CLIA) Analyzers Market is expected to register a CAGR of 6.4% during the forecast period, with a market value of USD 8,205.22 Million till 2026.
Chemiluminescence immunoassay (CLIA) analyzers have been growing at a rapid pace over the last few years.
The global chemiluminescence immunoassay (CLIA) analyzers market is rapidly booming due to the increasing prevalence of chronic and acute diseases, technological advancements, and high specificity provided by chemiluminescence immunoassay (CLIA) analyzers.
However, the scarcity of skilled labor/healthcare professionals and stringent regulatory policies are hampering the growth of the market.
Likewise, entry of market players in developing economies is likely to pose an opportunity for global chemiluminescence immunoassay (CLIA) analyzers market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/8783Segment AnalysisThe Global Chemiluminescence Immunoassay (CLIA) Analyzers Market is segmented into Type, Product, Application, and End User.
Based on the application, the global chemiluminescence immunoassay (CLIA) analyzers market has been categorized as hepatitis and retroviruses, oncology & endocrinology, cardiac markers, infectious disease, bone and mineral disorders, auto-immune diseases, allergy, GI stool testing, drug discovery and development, and others.
The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market.
The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.
Both top-down and bottom-up approaches were employed to estimate the complete market size.According to a new market research report “Non-Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) – Global Forecast to 2021″, published by MarketsandMarkets, The global NIPT market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period.Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.
However, a dearth of skilled professionals is restraining the growth of this market.Browse in-depth TOC on “Non-Invasive Prenatal Testing (NIPT) Market”110 tables48 figures150 pagesDownload PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=145607690The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies).
Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.The Non-Invasive Prenatal Testing Market is segmented based on product, method, application, end user, and region.
Factors such as high risk of chromosomal disorders with increasing maternal age and rising government investments are driving the growth of the NIPT market in this region.
Digital Pathology Market AnalysisDigital Pathology or Computational Pathology leverages completely new perceptions through data analysis, enabling pathologists to consult on treatment options.
Hence, pathology centers across the globe are increasingly adopting digital pathology to increase diagnostic speeds and accuracy.
According to Market Research Future (MRFR), the global digital pathology market is estimated for valuation of over USD 8,305.6 MN by 2023.
Additionally, the advanced medical services and the burgeoning healthcare sector worldwide are fostering the growth of the digital pathology market.
The demand for fast proceedings of treatments, with an accurate diagnosis, is rising, which results in the growth of the digital pathology market.The transition to cloud pathology is a prominent trend, observed during the analysis, which is expected to push up the growth in the market.
Technology experts think that machine learning and other sophisticated technologies could assist pathologists, making them more precise in their analysis.AI has the capacity of turning pathology into a digital zone.
